Arrivent Biopharma Inc.

Arrivent Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in patients with difficult-to-treat diseases, starting with cancers. Its lead development candidate, firmonertinib, a tyrosine kinase inhibitor, is being evaluated in multiple clinical trials for various epidermal growth factor receptor mutations in non-small cell lung cancer, including a Phase 3 trial for exon 20 insertion mutations and Phase 1b trials for activating mutations such as P-loop and alpha-c-helix compressing mutations. The company is also advancing ARR-217, an antibody drug conjugate targeting gastrointestinal cancers, and ARR-002 for solid tumors. Arrivent Biopharma Inc. leverages strategic collaborations with partners like Shanghai Allist Pharmaceuticals, Aarvik Therapeutics, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, and Lepu Biopharma to accelerate global development of innovative oncology therapeutics. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, it operates within the biotechnology sector of pharmaceuticals and biotech, emphasizing novel therapies like next-generation antibody drug conjugates.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Zhengbin Yao Ph.D.

Employees

77

Headquarters

Newtown Square, PA, United States

Website

arrivent.com